Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Chilam Chan, Marta Lustig, Niklas Baumann, Thomas Valerius, Geert van Tetering, Jeanette H.W. Leusen*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

8 Downloads (Pure)

Abstract

A Corrigendum onTargeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
by Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) 13:932155. doi: 10.3389/fimmu.2022.932155
Original languageEnglish
Article number1017924
Pages (from-to)1-2
JournalFrontiers in Immunology
Volume13
DOIs
Publication statusPublished - 13 Sept 2022

Keywords

  • antibodies
  • cancer immonotherapy
  • CD47-SIRPalpha axis
  • IgA
  • immune checkpoint
  • macrophages
  • myeloid checkpoints
  • neutrophils (PMNs)

Fingerprint

Dive into the research topics of 'Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?'. Together they form a unique fingerprint.

Cite this